Candida auris, what do paediatricians need to know?

Adilia Warris

Research output: Contribution to journalArticle

2 Citations (Scopus)
5 Downloads (Pure)

Abstract

The newly recognised and emerging fungal species, Candida auris, has caused worldwide invasive infections and has been implicated in difficult to control hospital outbreaks. Challenges are encountered in the correct identification of this fungus as commonly used phenotypic and biochemical methods fail to differentiate C. auris from other Candida species. Its resistance profile, over 90% of isolates are fluconazole resistant and 35% are resistant to amphotericin, confronts clinicians with the restricted arsenal of antifungals and concerns about optimal treatment. The very first C. auris isolate was recovered from a paediatric patient in retrospect. Although infections with the more antifungal-resistant Candida species are less frequently observed in paediatric patients, this seems to be different for C. auris infections.
Original languageEnglish
Pages (from-to)891-894
Number of pages4
JournalArchives of Disease in Childhood
Volume103
Issue number9
Early online date15 Mar 2018
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Candida
Infection
Pediatrics
Fluconazole
Amphotericin B
Disease Outbreaks
Fungi
Pediatricians
Therapeutics

Cite this

Candida auris, what do paediatricians need to know? / Warris, Adilia.

In: Archives of Disease in Childhood, Vol. 103, No. 9, 09.2018, p. 891-894.

Research output: Contribution to journalArticle

Warris, Adilia. / Candida auris, what do paediatricians need to know?. In: Archives of Disease in Childhood. 2018 ; Vol. 103, No. 9. pp. 891-894.
@article{7a64bbcd4b374ed1ba75af330eb90a21,
title = "Candida auris, what do paediatricians need to know?",
abstract = "The newly recognised and emerging fungal species, Candida auris, has caused worldwide invasive infections and has been implicated in difficult to control hospital outbreaks. Challenges are encountered in the correct identification of this fungus as commonly used phenotypic and biochemical methods fail to differentiate C. auris from other Candida species. Its resistance profile, over 90{\%} of isolates are fluconazole resistant and 35{\%} are resistant to amphotericin, confronts clinicians with the restricted arsenal of antifungals and concerns about optimal treatment. The very first C. auris isolate was recovered from a paediatric patient in retrospect. Although infections with the more antifungal-resistant Candida species are less frequently observed in paediatric patients, this seems to be different for C. auris infections.",
author = "Adilia Warris",
note = "AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.",
year = "2018",
month = "9",
doi = "10.1136/archdischild-2017-313960",
language = "English",
volume = "103",
pages = "891--894",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Candida auris, what do paediatricians need to know?

AU - Warris, Adilia

N1 - AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.

PY - 2018/9

Y1 - 2018/9

N2 - The newly recognised and emerging fungal species, Candida auris, has caused worldwide invasive infections and has been implicated in difficult to control hospital outbreaks. Challenges are encountered in the correct identification of this fungus as commonly used phenotypic and biochemical methods fail to differentiate C. auris from other Candida species. Its resistance profile, over 90% of isolates are fluconazole resistant and 35% are resistant to amphotericin, confronts clinicians with the restricted arsenal of antifungals and concerns about optimal treatment. The very first C. auris isolate was recovered from a paediatric patient in retrospect. Although infections with the more antifungal-resistant Candida species are less frequently observed in paediatric patients, this seems to be different for C. auris infections.

AB - The newly recognised and emerging fungal species, Candida auris, has caused worldwide invasive infections and has been implicated in difficult to control hospital outbreaks. Challenges are encountered in the correct identification of this fungus as commonly used phenotypic and biochemical methods fail to differentiate C. auris from other Candida species. Its resistance profile, over 90% of isolates are fluconazole resistant and 35% are resistant to amphotericin, confronts clinicians with the restricted arsenal of antifungals and concerns about optimal treatment. The very first C. auris isolate was recovered from a paediatric patient in retrospect. Although infections with the more antifungal-resistant Candida species are less frequently observed in paediatric patients, this seems to be different for C. auris infections.

U2 - 10.1136/archdischild-2017-313960

DO - 10.1136/archdischild-2017-313960

M3 - Article

VL - 103

SP - 891

EP - 894

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 9

ER -